Medexus Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Medexus Pharmaceuticals generated cash of $18,714,000, which is more than the previous year. Cash used in financing activities reached the amount of -$23,048,000 last year. Net change in cash is therefore -$7,814,000.
Cash Flow
| 2012 | -8.96K | 0 | 176.04K |
|---|---|---|---|
| 2016 | -990.95K | -507.78K | 67.91K |
| 2018 | -2.99M | -563.49K | 3.83M |
| 2020 | -1.62M | -28.57M | 14.60M |
| 2021 | 5.03M | -11.70M | 18.68M |
| 2023 | -1.44M | -1.72M | 6.40M |
| 2024 | 18.71M | -3.47M | -23.04M |
MDP.TO Cash Flow Statement (2013 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | 2013 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 13.06M | 10.01M | 5.23M | 20.59M | 2.50M | 5.23M | 373.52K |
Operating activities | |||||||
Net income | -214K | 1.22M | -28.26M | -4.39M | -2.69M | -1.77M | -149.56K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 5.80M | 6.08M | 5.97M | 3.70M | 178.99K | 113.48K | 0 |
Stock-based compensation expense | 469K | 1.21M | 1.27M | 1.47M | 207.37K | 403.35K | 94.75K |
| Deferred income tax benefit | 469K | 1.21M | 1.27M | 1.47M | 207.37K | 403.35K | 94.75K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -1.67M | -8.23M | -3.50M | -7.25M | -100.01K | 778 | 0 |
Inventories | -6.75M | -1.98M | -9K | 997.03K | -375.35K | -184.66K | 0 |
Accounts payable | 11.57M | -5.04M | 6.11M | -4 | -254.73K | -226.28K | 0 |
Cash generated by operating activities | 18.71M | -1.44M | 5.03M | -1.62M | -2.99M | -990.95K | -8.96K |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -50K | -362K | -10.75M | -841.91K | -563.49K | -507.78K | 0 |
Acquisitions Net | -3.21M | -1.35M | -952K | -27.93M | 0 | 0 | 0 |
Cash generated by investing activities | -3.47M | -1.72M | -11.70M | -28.57M | -563.49K | -507.78K | 0 |
Financing activities | |||||||
Common Stock Issued | 7.60M | 0 | 22.63M | 0 | 3.83M | 71.23K | 301.55K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -2.63M | 0 | 0 | 0 |
Repayments of term debt | -26.40M | 10.73M | -369K | 0 | 0 | -4.30K | 0 |
Cash used in financing activities | -23.04M | 6.40M | 18.68M | 14.60M | 3.83M | 67.91K | 176.04K |
Net Change In Cash | -7.81M | 3.05M | 13.47M | -15.35M | 284.50K | -1.43M | 167.08K |
Cash at end of period | 5.25M | 13.06M | 18.70M | 5.23M | 2.79M | 3.80M | 540.60K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |